OncRef

Clinical Trial: NCT05775796

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Fudan University
Information Provided By:Fudan University
Last Update Posted:2025-10-01

Study Overview

Brief Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and chemotherapy in treating resectable Non-Small Cell Lung Cancer(NSCLC). The study also intended to explore the immune function of tumor-draining lymph nodes during immunotherapy.

Official Title

A Single-arm, Multicenter, and Phase II Clinical Study to Evaluate the Efficacy and Safety of Serplulimab Combined With Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable Stage II-IIIA NSCLC

Conditions

Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy

Intervention / Treatment

  • Drug: Serplulimab and Chemotherapy

Other Study ID Numbers

  • HLX10IIT21

Start Date (Actual)

2023-03-15

Primary Completion Date (Actual)

2024-05-28

Study Completion Date (Actual)

2025-09-01

Enrollment (Actual)

30

Study Type

Interventional

Phase

Phase 2